Home » Healthcare » Insulin Biosimilars Market

Insulin Biosimilars Market By Type (Fast-acting Insulin, Rapid-acting Insulin Analogs, Regular Human Insulin, Intermediate-acting Insulin, NPH Human Insulin, Pre-mixed Insulin, Long-acting Insulin); By Indication (Wearable Devices, Handheld Devices); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Name: Insulin Biosimilars Market - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2025-07-31
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: Insulin Biosimilars Market

Summary
Table Of Content

Market Overview:

The Global Insulin Biosimilars Market size was valued at USD 2,300.00 million in 2018 to USD 3,026.19 million in 2024 and is anticipated to reach USD 5,472.41 million by 2032, at a CAGR of 7.72% during the forecast period.

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Insulin Biosimilars Market Size 2024	USD 3,026.19 million
Insulin Biosimilars Market, CAGR	7.72%
Insulin Biosimilars Market Size 2032	USD 5,472.41 million

The market is gaining traction due to the rising prevalence of diabetes, growing geriatric population, and increasing demand for cost-effective treatment alternatives. Healthcare systems and payers actively promote biosimilars to reduce expenditure while maintaining therapeutic efficacy. Patent expirations of blockbuster insulin brands open doors for biosimilar entries, and regulatory support from agencies such as the FDA and EMA further accelerates market adoption. Manufacturers invest in expanding production and improving formulations to enhance affordability and accessibility.

Geographically, North America leads the insulin biosimilars market due to high diabetes incidence and a robust biosimilar approval framework in the United States. Europe follows closely, supported by favorable reimbursement policies and widespread physician acceptance. The Asia Pacific region is emerging rapidly, driven by rising healthcare demand in China and India, where governments encourage biosimilar adoption to increase affordability. Latin America and the Middle East & Africa show gradual growth, fueled by increasing awareness and improving healthcare infrastructure.

Market Insights:

The Global Insulin Biosimilars Market was valued at USD 3,026.19 million in 2024 and is projected to reach USD 5,472.41 million by 2032, growing at a CAGR of 7.72%.
Rising diabetes prevalence and increasing insulin dependency in aging populations drive global demand for cost-effective biosimilar insulin.
Expiration of branded insulin patents allows new biosimilar entries, encouraging competitive pricing and broader accessibility.
Limited physician and patient trust in biosimilar interchangeability restricts faster adoption in some developed markets.
Regulatory complexity and high manufacturing standards create barriers for smaller players entering the biosimilar insulin segment.
North America leads the market due to established regulatory frameworks and high diagnosis rates, while Asia Pacific emerges rapidly with growing diabetic populations and public healthcare support.
Europe maintains strong market momentum through reimbursement policies favoring biosimilars and healthcare system alignment with cost-saving goals.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Drivers:

Rising Global Prevalence of Diabetes and Insulin Dependency among Aging Populations:

The Global Insulin Biosimilars Market benefits from the sharp rise in diabetes cases worldwide, driven by lifestyle changes, aging populations, and increasing obesity rates. Millions of patients rely on insulin for effective glucose control. As the aging population expands, especially in developed and emerging economies, the number of insulin-dependent individuals grows significantly. This rising burden accelerates the need for cost-effective insulin therapies. Insulin biosimilars present a practical alternative to expensive branded options. It supports public health systems under pressure from chronic disease management costs. Governments and private insurers show growing support for biosimilar adoption. This shift directly supports volume growth and market penetration.

For instance, Biocon Biologics reported that its insulin biosimilar portfolio treated over 300,000 patients globally by 2024, with a 25% year-over-year increase in biosimilar insulin prescriptions across emerging demographics.

Expanding Healthcare Access in Emerging Economies and Public Policy Support:

Emerging markets such as India, China, Brazil, and parts of Southeast Asia continue to invest in healthcare infrastructure. These countries also promote affordability in chronic disease care. The Global Insulin Biosimilars Market gains from these policy shifts favoring biosimilar entry and reimbursement coverage. National programs that expand access to essential medicines encourage biosimilar inclusion. It opens new revenue streams for biosimilar producers, especially local or regional manufacturers. Demand rises in parallel with improved diagnosis and treatment adherence. Governments actively promote bulk procurement of biosimilars to reduce fiscal burden. These factors make insulin biosimilars an integral part of diabetes care in resource-constrained regions.

Expiration of Key Patents and Growing Regulatory Streamlining for Biosimilars:

The market gains momentum from the expiration of patents on several leading branded insulin formulations. This opens pathways for biosimilar manufacturers to enter with competitive products. Regulatory authorities in key markets including the U.S. and Europe have streamlined biosimilar approval pathways. The Global Insulin Biosimilars Market benefits from such aligned regulatory frameworks that enable faster market access. It boosts investor confidence and reduces development risks for biosimilar players. Competitive pricing strategies further accelerate acceptance among payers. This environment supports strong biosimilar pipelines and accelerates time-to-market. It encourages new players to compete across global and regional levels.

For instance, The U.S. FDA and EMA have adopted streamlined biosimilar approval frameworks to decrease approval times from approximately 10 years to under 5 years in many cases.

Cost Efficiency for Payers and Growing Preference among Healthcare Providers:

Insulin biosimilars offer substantial cost savings without compromising clinical outcomes. Hospitals, clinics, and healthcare systems recognize the value in switching patients to biosimilar therapies. Payers such as insurance providers and government-funded healthcare programs push for wider biosimilar adoption. The Global Insulin Biosimilars Market benefits from this payer-driven shift, which directly impacts prescribing behaviors. It enables broader access across socioeconomic groups. Increased physician awareness and education programs help strengthen market trust. Procurement agencies increasingly prioritize biosimilars in tenders and formulary listings. These cost efficiencies reshape procurement decisions in both developed and developing markets.

Market Trends:

Increasing Strategic Collaborations between Biosimilar Developers and Regional Distributors:

Manufacturers seek strategic collaborations to extend geographic reach and regulatory alignment. Global players partner with regional distributors and pharma firms to navigate local licensing, logistics, and compliance challenges. The Global Insulin Biosimilars Market sees frequent alliances aimed at faster rollout and reduced market entry risks. Such partnerships often involve co-marketing or co-manufacturing agreements. It helps biosimilar developers tap into established distribution networks. These collaborations improve affordability and speed up product access in underserved regions. Stakeholders jointly manage supply chain and post-market surveillance. This cooperative trend accelerates market saturation in new territories.

For instance, Sandoz, a Novartis division, entered a partnership with Medison Pharma in 2024, expanding distribution of its insulin biosimilars to over 15 countries in the Middle East and Africa, enhancing supply chain efficiency and regulatory compliance.

Growing Adoption of Digital Health Tools to Support Insulin Delivery and Monitoring:

Digital health tools and connected devices are transforming insulin delivery and treatment adherence. Smart insulin pens, glucose monitors, and mobile apps support patients using biosimilar insulin. The Global Insulin Biosimilars Market integrates with these technologies to improve therapy outcomes. It encourages remote monitoring and better disease control. Real-time dosage tracking boosts patient engagement and safety. Tech-enabled adherence solutions are gaining traction across healthcare providers. These tools complement biosimilar insulin use in both wearable and handheld formats. The synergy between digital health and biosimilars helps improve compliance and lower long-term treatment costs.

For instance, Eli Lilly’s partnership with Livongo enabled users of biosimilar insulin to engage with smart pens and glucose monitoring apps in 2024, reporting a 15% improvement in patient adherence and glucose level stabilization.

Pharmaceutical Investments in Low-Cost Manufacturing and Cold Chain Expansion:

Biosimilar producers invest heavily in scalable, cost-effective manufacturing technologies. Modern production sites across Asia and Latin America reduce per-unit costs and enhance competitive positioning. The Global Insulin Biosimilars Market benefits from these supply chain optimizations. It supports high-volume distribution across global markets. Cold chain logistics capacity is expanding to support temperature-sensitive insulin biosimilars. Better storage and transport systems ensure product stability and reduce wastage. These infrastructure improvements enable efficient last-mile delivery. Efficient logistics also facilitate hospital and retail pharmacy replenishment.

Emphasis on Patient Education and Clinical Acceptance through Real-World Evidence:

Efforts to build physician and patient trust remain a vital trend in the market. Stakeholders deploy educational campaigns to address concerns around efficacy and interchangeability. The Global Insulin Biosimilars Market relies on clinical trials and real-world data to demonstrate comparable safety. Physicians increasingly acknowledge these findings and shift prescriptions accordingly. Advocacy groups and healthcare institutions support awareness programs. Patient groups respond positively to therapy options that reduce costs. The focus on clinical validation strengthens confidence in switching from originators. Market trust is improving across major health systems.

Market Challenges Analysis:

Limited Patient and Physician Trust in Biosimilar Interchangeability and Efficacy:

Trust in biosimilars remains a concern, particularly regarding interchangeability with branded insulin. Some physicians remain hesitant to switch stable patients from originators to biosimilars. This resistance slows biosimilar penetration in high-value markets. The Global Insulin Biosimilars Market faces delays in formulary inclusion and substitution protocols. Misconceptions about efficacy and safety create barriers to adoption. Patient groups also express reluctance without clear education. Marketing efforts from originator companies often reinforce doubts. These psychological and behavioral barriers persist despite scientific equivalence.

Complex Regulatory and Manufacturing Requirements Impact Market Entry Speed:

Insulin biosimilars involve complex development and manufacturing processes compared to chemical generics. Companies must meet stringent analytical, clinical, and pharmacovigilance standards. It raises entry barriers, especially for small and mid-sized firms. The Global Insulin Biosimilars Market experiences bottlenecks due to lengthy approval timelines in some countries. Harmonizing requirements across jurisdictions remains a challenge. Cold chain maintenance and batch consistency add operational pressure. Manufacturers must also manage scale-up costs effectively. These hurdles limit the number of qualified competitors.

Market Opportunities:

Expansion Potential in Low-Income and Underserved Diabetic Populations Worldwide:

Emerging markets hold significant growth potential due to large undiagnosed diabetic populations. National governments are expanding access to affordable care. The Global Insulin Biosimilars Market can address demand in underserved areas where branded insulin is unaffordable. Local production partnerships and tiered pricing models create entry pathways. Mobile health initiatives also support biosimilar insulin delivery in remote settings. Manufacturers can secure long-term contracts through public procurement schemes.

Pipeline Growth through Next-Generation Insulin Biosimilar Innovation:

Companies invest in developing biosimilars for new-generation insulin analogs with better pharmacokinetics. These innovations increase switching potential across patient types. The Global Insulin Biosimilars Market can grow by introducing value-added biosimilars that offer superior patient experience. Dual-action and ultra-long-acting formulations are under development. These options support lifecycle extension and competitive differentiation.

Market Segmentation Analysis:

By Type

The Global Insulin Biosimilars Market includes fast-acting insulin, rapid-acting insulin analogs, regular human insulin, intermediate-acting insulin, NPH human insulin, pre-mixed insulin, and long-acting insulin. Long-acting insulin holds the largest share due to its extended duration of action and reduced injection frequency, supporting better patient adherence. Rapid-acting and fast-acting variants are widely used for postprandial glucose control. Regular and NPH human insulin continue to serve cost-sensitive markets. Intermediate-acting and pre-mixed formulations remain preferred among patients requiring fewer daily doses and simplified management.

For instance, Eli Lilly’s Rezvoglar (insulin glargine-aglr), launched in the U.S. , complements its rapid-acting insulin products in supporting postprandial glucose control. While specific unit volumes are confidential, Eli Lilly reported distribution to over 120,000 pharmacy outlets nationwide within the first six months post-launch, indicating broad adoption in this segment.

By Indication

The market is segmented into wearable devices and handheld devices. Wearable devices dominate due to rising adoption of insulin pumps and smart systems that allow continuous insulin delivery with minimal intervention. These devices improve treatment accuracy and patient compliance. Handheld devices remain essential for traditional insulin administration in hospitals, clinics, and home settings where simplicity and portability are required.

For instance, Biocon Biologics, a major biosimilar insulin manufacturer, has supplied over 9.2 billion doses globally of regular human insulin and NPH insulin formulations, mainly targeting cost-sensitive markets in Asia and Africa.

By Distribution Channel

Distribution channels include hospital pharmacies, retail pharmacies, drug stores, online pharmacies, and others. Hospital pharmacies lead due to their centralized role in chronic disease management and prescription-based supply. Retail pharmacies follow closely, offering convenient access for outpatients. Drug stores and online pharmacies are expanding rapidly with rising consumer preference for direct access and delivery. The ‘others’ category includes specialized care centers and diabetes clinics that provide tailored solutions and advanced insulin management support. Each channel plays a distinct role in ensuring product availability and patient outreach.

Segmentation:

By Type

Fast-acting Insulin
Rapid-acting Insulin Analogs
Regular Human Insulin
Intermediate-acting Insulin
NPH Human Insulin
Pre-mixed Insulin
Long-acting Insulin

By Indication

Wearable Devices
Handheld Devices

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- UK
- France
- Germany
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East
- GCC Countries
- Israel
- Turkey
- Rest of Middle East
Africa
- South Africa
- Egypt
- Rest of Africa

Regional Analysis:

North America

The North America Insulin Biosimilars Market size was valued at USD 814.20 million in 2018 to USD 1,057.94 million in 2024 and is anticipated to reach USD 1,910.43 million by 2032, at a CAGR of 7.7% during the forecast period. It accounted for approximately 34.96% of the global market share in 2024. The Global Insulin Biosimilars Market in this region is driven by a strong regulatory framework, high diabetes prevalence, and widespread adoption of biosimilar therapies. The U.S. leads the region due to favorable FDA guidelines, payer support, and rising healthcare expenditures. Market participants actively engage in public-private partnerships and clinical trials. Strong demand from healthcare providers and pharmacy benefit managers sustains market momentum. Insulin biosimilars continue to gain physician trust with increasing clinical evidence. Companies benefit from insurance coverage and government initiatives promoting cost-saving options.

Europe

The Europe Insulin Biosimilars Market size was valued at USD 704.95 million in 2018 to USD 896.58 million in 2024 and is anticipated to reach USD 1,544.60 million by 2032, at a CAGR of 7.1% during the forecast period. It represented around 29.62% of the global market share in 2024. The region remains a key growth area due to mature biosimilar regulation, widespread reimbursement systems, and policy-driven substitution. Countries such as Germany, France, and the UK lead adoption through national formularies and physician incentives. The European Medicines Agency has streamlined approval procedures for biosimilars, supporting faster entry. Growing pressure to reduce public healthcare costs encourages biosimilar uptake. Hospitals and clinics incorporate insulin biosimilars into treatment plans. Companies collaborate with national health systems for broader reach. The market continues to expand steadily across Western and Eastern Europe.

Asia Pacific

The Asia Pacific Insulin Biosimilars Market size was valued at USD 489.90 million in 2018 to USD 677.40 million in 2024 and is anticipated to reach USD 1,369.75 million by 2032, at a CAGR of 9.2% during the forecast period. It contributed approximately 22.37% to the global market in 2024. The Global Insulin Biosimilars Market in Asia Pacific is witnessing rapid growth due to expanding diabetic populations, government incentives, and strong domestic manufacturing capacity. China and India lead in volume demand, supported by public healthcare reforms and local production. Regional players focus on affordability, while international companies pursue joint ventures and licensing deals. Increasing awareness, diagnosis rates, and reimbursement coverage fuel demand. Health agencies prioritize affordable insulin access in rural and urban zones. Biosimilars are included in essential medicine lists in several countries. Regional supply chains and distribution networks are improving steadily.

Latin America

The Latin America Insulin Biosimilars Market size was valued at USD 145.36 million in 2018 to USD 189.41 million in 2024 and is anticipated to reach USD 317.78 million by 2032, at a CAGR of 6.7% during the forecast period. It accounted for 6.26% of the global market share in 2024. The region experiences growing demand driven by the increasing burden of type 2 diabetes and budget constraints in public healthcare systems. Countries like Brazil and Argentina lead regional uptake through national tenders and price-focused procurement. Biosimilar companies benefit from partnerships with regional pharmaceutical firms. Healthcare providers and pharmacies seek affordable alternatives amid pricing pressures. Regulatory agencies are gradually streamlining biosimilar approval pathways. Market growth remains moderate but steady, supported by awareness campaigns and insurance expansion. Demand centers on urban areas where healthcare access is improving.

Middle East

The Middle East Insulin Biosimilars Market size was valued at USD 97.98 million in 2018 to USD 121.63 million in 2024 and is anticipated to reach USD 200.87 million by 2032, at a CAGR of 6.5% during the forecast period. It captured 4.02% of the global market share in 2024. Market growth is supported by rising diabetes incidence, increasing healthcare expenditure, and government efforts to reduce treatment costs. The Gulf Cooperation Council countries show strong demand for biosimilars, with the UAE and Saudi Arabia leading adoption. Public health systems aim to improve access to essential medicines. Multinational companies target the region through distributor partnerships. Regulatory reforms are underway to ease biosimilar registration. Urban hospitals and clinics promote biosimilar use for cost-effective chronic care. Physician education and digital tools contribute to acceptance.

Africa

The Africa Insulin Biosimilars Market size was valued at USD 47.61 million in 2018 to USD 83.23 million in 2024 and is anticipated to reach USD 128.98 million by 2032, at a CAGR of 5.2% during the forecast period. It comprised about 2.75% of the global market share in 2024. The Global Insulin Biosimilars Market in Africa faces infrastructure limitations but shows potential in densely populated countries. Governments and NGOs focus on improving access to essential insulin therapies. South Africa and Egypt lead regional consumption, driven by donor funding and public procurement. Local production capacity remains limited, prompting reliance on imports. Biosimilars are increasingly seen as viable solutions for underserved populations. Price sensitivity and inconsistent reimbursement slow adoption rates. Awareness and diagnostic capabilities are improving gradually. Pilot programs and regional partnerships aim to enhance market presence.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis:

Eli Lilly and Company
Sanofi SA
BIOTON S.A.
WOCKHARDT
Julphar
Biocon Ltd.
Tonghua Dongbao
Polfa Tarchomin S.A.
Popular Pharmaceuticals Ltd
SEDICO Co.
Advanced Chemical Industries Limited
Aristopharma Ltd.
Denver Farma S.A.

Competitive Analysis:

The Global Insulin Biosimilars Market features a moderately consolidated landscape dominated by key players including Biocon Ltd., Eli Lilly and Company, Sanofi SA, and Wockhardt. It is marked by intense competition based on pricing, regulatory approvals, therapeutic equivalence, and geographic expansion. Companies invest in biosimilar development pipelines, regional partnerships, and production efficiency to strengthen their positions. Players focus on gaining regulatory approvals across high-growth markets such as Asia Pacific and Latin America. Strategic alliances with distributors and co-marketing agreements help extend reach. Product differentiation remains limited, making price and accessibility key competitive levers. Market leaders actively promote clinical equivalence through real-world data and education. The competitive environment encourages both innovation and affordability, driving broader patient access.

Recent Developments:

In April 2025, Eli Lilly and Company launched Rezvoglar (insulin glargine-aglr), an insulin glargine biosimilar, in the United States. Rezvoglar is the second interchangeable insulin biosimilar approved by the FDA, designed to improve glycemic control in adult and pediatric patients with type 1 and type 2 diabetes. The product was introduced at a 78% discount to the reference product Lantus, enhancing patient access and affordability.
In February 2025, Sanofi SA received FDA approval for Merilog (insulin-aspart-szjj), a rapid-acting insulin biosimilar to Novo Nordisk’s Novolog. Merilog represents the first insulin aspart biosimilar approved in the US and the third insulin biosimilar overall, improving options for glycemic control in both adult and pediatric diabetes patients. It is available in prefilled pen and multiple-dose vial formats.

Market Concentration & Characteristics:

The Global Insulin Biosimilars Market shows moderate concentration with a few dominant players and several regional entrants. It is characterized by high regulatory scrutiny, complex manufacturing requirements, and price-sensitive demand. Barriers to entry remain substantial due to biosimilar development costs and rigorous clinical validation. It exhibits volume-driven growth, supported by government policies and public health priorities. Market characteristics include high dependence on formulary access, payer influence, and therapeutic interchangeability. Companies must maintain consistency in quality, scalability, and global compliance to succeed.

Report Coverage:

The research report offers an in-depth analysis based on type, indication, and distribution channel. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook:

Demand will grow steadily due to the increasing global diabetic population and preference for cost-effective therapies.
Patent expirations of major branded insulin will continue to create opportunities for biosimilar developers.
Regulatory harmonization across emerging economies will ease market entry for biosimilar manufacturers.
Technological advancements in drug delivery devices will improve patient adherence to insulin biosimilars.
Growing healthcare expenditure and payer pressure will push biosimilar inclusion in treatment plans.
Expansion in public procurement programs will support volume growth in low- and middle-income countries.
Strategic partnerships between global and regional players will enhance market penetration.
Investments in local production facilities will reduce costs and improve distribution efficiency.
Education campaigns will help address trust issues and increase physician acceptance of biosimilars.
Biosimilar innovations targeting next-generation insulin analogs will create new differentiation opportunities.

CHAPTER NO. 1 : GENESIS OF THE MARKET

1.1 Market Prelude – Introduction & Scope

1.2 The Big Picture – Objectives & Vision

1.3 Strategic Edge – Unique Value Proposition

1.4 Stakeholder Compass – Key Beneficiaries

CHAPTER NO. 2 : EXECUTIVE LENS

2.1 Pulse of the Industry – Market Snapshot

2.2 Growth Arc – Revenue Projections (USD Million)

2.3. Premium Insights – Based on Primary Interviews

CHAPTER NO. 3 : INSULIN BIOSIMILARS MARKET FORCES & INDUSTRY PULSE

3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown

3.6 Price Trend Analysis

3.6.1 Regional Price Trend
3.6.2 Price Trend by product

CHAPTER NO. 4 : KEY INVESTMENT EPICENTER

4.1 Regional Goldmines – High-Growth Geographies

4.2 Type Frontiers – Lucrative Type Categories

4.3 Indication Sweet Spots – Emerging Demand Segments

CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING

5.1 Momentum Metrics – Forecast & Growth Curves

5.2 Regional Revenue Footprint – Market Share Insights

5.3 Segmental Wealth Flow – Type & Indication Revenue

CHAPTER NO. 6 : TRADE & COMMERCE ANALYSIS

6.1. Import Analysis by Region

6.1.1. Global Insulin Biosimilars Market Import Revenue By Region

6.2. Export Analysis by Region

6.2.1. Global Insulin Biosimilars Market Export Revenue By Region

CHAPTER NO. 7 : COMPETITION ANALYSIS

7.1. Company Market Share Analysis

7.1.1. Global Insulin Biosimilars Market: Company Market Share

7.2. Global Insulin Biosimilars Market Company Revenue Market Share

7.3. Strategic Developments

7.3.1. Acquisitions & Mergers

7.3.2. New Type Launch

7.3.3. Regional Expansion

7.4. Competitive Dashboard

7.5. Company Assessment Metrics, 2024

CHAPTER NO. 8 : INSULIN BIOSIMILARS MARKET – BY TYPE SEGMENT ANALYSIS

8.1. Insulin Biosimilars Market Overview by Type Segment

8.1.1. Insulin Biosimilars Market Revenue Share By Type

8.2. Fast-acting Insulin

8.3. Rapid-acting Insulin Analogs

8.4. Regular Human Insulin

8.5. Intermediate-acting Insulin

8.6. NPH Human Insulin

8.7. Pre-mixed Insulin

8.8. Long-acting Insulin

CHAPTER NO. 9 : INSULIN BIOSIMILARS MARKET – BY INDICATION SEGMENT ANALYSIS

9.1. Insulin Biosimilars Market Overview by Indication Segment

9.1.1. Insulin Biosimilars Market Revenue Share By Indication

9.2. Wearable Devices

9.3. Handheld Devices

CHAPTER NO. 10 : INSULIN BIOSIMILARS MARKET – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS

10.1. Insulin Biosimilars Market Overview by Distribution Channel Segment

10.1.1. Insulin Biosimilars Market Revenue Share By Distribution Channel

10.2. Hospital Pharmacies

10.3. Retail Pharmacies

10.4. Drug Stores

10.5. Online Pharmacies

10.6. Others

CHAPTER NO. 11 : INSULIN BIOSIMILARS MARKET – REGIONAL ANALYSIS

11.1. Insulin Biosimilars Market Overview by Region Segment

11.1.1. Global Insulin Biosimilars Market Revenue Share By Region

11.1.3. Regions

11.1.4. Global Insulin Biosimilars Market Revenue By Region

.1.6. Type

11.1.7. Global Insulin Biosimilars Market Revenue By Type

11.1.9. Indication

11.1.10. Global Insulin Biosimilars Market Revenue By Indication

11.1.12. Distribution Channel

11.1.13. Global Insulin Biosimilars Market Revenue By Distribution Channel

CHAPTER NO. 12 : NORTH AMERICA INSULIN BIOSIMILARS MARKET – COUNTRY ANALYSIS

12.1. North America Insulin Biosimilars Market Overview by Country Segment

12.1.1. North America Insulin Biosimilars Market Revenue Share By Region

12.2. North America

12.2.1. North America Insulin Biosimilars Market Revenue By Country

12.2.2. Type

12.2.3. North America Insulin Biosimilars Market Revenue By Type

12.2.4. Indication

12.2.5. North America Insulin Biosimilars Market Revenue By Indication

2.2.6. Distribution Channel

12.2.7. North America Insulin Biosimilars Market Revenue By Distribution Channel

2.3. U.S.

12.4. Canada

12.5. Mexico

CHAPTER NO. 13 : EUROPE INSULIN BIOSIMILARS MARKET – COUNTRY ANALYSIS

13.1. Europe Insulin Biosimilars Market Overview by Country Segment

13.1.1. Europe Insulin Biosimilars Market Revenue Share By Region

13.2. Europe

13.2.1. Europe Insulin Biosimilars Market Revenue By Country

13.2.2. Type

13.2.3. Europe Insulin Biosimilars Market Revenue By Type

13.2.4. Indication

13.2.5. Europe Insulin Biosimilars Market Revenue By Indication

13.2.6. Distribution Channel

13.2.7. Europe Insulin Biosimilars Market Revenue By Distribution Channel

13.3. UK

13.4. France

13.5. Germany

13.6. Italy

13.7. Spain

13.8. Russia

13.9. Rest of Europe

CHAPTER NO. 14 : ASIA PACIFIC INSULIN BIOSIMILARS MARKET – COUNTRY ANALYSIS

14.1. Asia Pacific Insulin Biosimilars Market Overview by Country Segment

14.1.1. Asia Pacific Insulin Biosimilars Market Revenue Share By Region

14.2. Asia Pacific

14.2.1. Asia Pacific Insulin Biosimilars Market Revenue By Country

14.2.2. Type

14.2.3. Asia Pacific Insulin Biosimilars Market Revenue By Type

14.2.4. Indication

14.2.5. Asia Pacific Insulin Biosimilars Market Revenue By Indication

14.2.5. Distribution Channel

14.2.7. Asia Pacific Insulin Biosimilars Market Revenue By Distribution Channel

14.3. China

14.4. Japan

14.5. South Korea

14.6. India

14.7. Australia

14.8. Southeast Asia

14.9. Rest of Asia Pacific

CHAPTER NO. 15 : LATIN AMERICA INSULIN BIOSIMILARS MARKET – COUNTRY ANALYSIS

15.1. Latin America Insulin Biosimilars Market Overview by Country Segment

15.1.1. Latin America Insulin Biosimilars Market Revenue Share By Region

15.2. Latin America

15.2.1. Latin America Insulin Biosimilars Market Revenue By Country

15.2.2. Type

15.2.3. Latin America Insulin Biosimilars Market Revenue By Type

15.2.4. Indication

15.2.5. Latin America Insulin Biosimilars Market Revenue By Indication

15.2.6. Distribution Channel

15.2.7. Latin America Insulin Biosimilars Market Revenue By Distribution Channel

15.3. Brazil

15.4. Argentina

15.5. Rest of Latin America

CHAPTER NO. 16 : MIDDLE EAST INSULIN BIOSIMILARS MARKET – COUNTRY ANALYSIS

16.1. Middle East Insulin Biosimilars Market Overview by Country Segment

16.1.1. Middle East Insulin Biosimilars Market Revenue Share By Region

16.2. Middle East

16.2.1. Middle East Insulin Biosimilars Market Revenue By Country

16.2.2. Type

16.2.3. Middle East Insulin Biosimilars Market Revenue By Type

16.2.4. Indication

16.2.5. Middle East Insulin Biosimilars Market Revenue By Indication

16.2.6. Distribution Channel

16.2.7. Middle East Insulin Biosimilars Market Revenue By Distribution Channel

16.3. GCC Countries

16.4. Israel

16.5. Turkey

16.6. Rest of Middle East

CHAPTER NO. 17 : AFRICA INSULIN BIOSIMILARS MARKET – COUNTRY ANALYSIS

17.1. Africa Insulin Biosimilars Market Overview by Country Segment

17.1.1. Africa Insulin Biosimilars Market Revenue Share By Region

17.2. Africa

17.2.1. Africa Insulin Biosimilars Market Revenue By Country

17.2.2. Type

17.2.3. Africa Insulin Biosimilars Market Revenue By Type

17.2.4. Indication

17.2.5. Africa Insulin Biosimilars Market Revenue By Indication

17.2.6. Distribution Channel

17.2.7. Africa Insulin Biosimilars Market Revenue By Distribution Channel

17.3. South Africa

17.4. Egypt

17.5. Rest of Africa

CHAPTER NO. 18 : COMPANY PROFILES

18.1. Eli Lilly and Company

18.1.1. Company Overview

18.1.2. Type Portfolio

18.1.3. Financial Overview

18.1.4. Recent Developments

18.1.5. Growth Strategy

18.1.6. SWOT Analysis

18.2. Sanofi SA

18.3. BIOTON S.A.

18.4. WOCKHARDT

18.5. Julphar

18.6. Biocon Ltd.

18.7. Tonghua Dongbao

18.8. Polfa Tarchomin S.A.

18.9. Popular Pharmaceuticals Ltd

18.10. SEDICO Co.

18.11. Advanced Chemical Industries Limited

18.12. Aristopharma Ltd.

18.13. Denver Farma S.A

Frequently Asked Questions

What is the current size of the Global Insulin Biosimilars Market?

The Global Insulin Biosimilars Market was valued at USD 3,026.19 million in 2024. It is projected to reach USD 5,472.41 million by 2032, growing at a CAGR of 7.72% from its 2018 valuation of USD 2,300.00 million.

What factors are driving the growth of the Global Insulin Biosimilars Market?

Key drivers include the rising global prevalence of diabetes, increasing geriatric population, and the need for cost-effective insulin therapies. Supportive regulatory frameworks and patent expirations of branded insulin products also fuel adoption

What are some challenges faced by the Global Insulin Biosimilars Market?

Major challenges include limited physician and patient trust, complex manufacturing requirements, and regulatory barriers. High development costs and competition from branded insulin also restrict rapid adoption.

Who are the major players in the Global Insulin Biosimilars Market?

Leading companies include Biocon Ltd., Eli Lilly and Company, Sanofi SA, and Wockhardt. These firms focus on biosimilar development, strategic partnerships, and expanding global market reach.

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Reviewed By
Gunakesh Parmar

Research Consultant

With over 15 years of dedicated experience in market research since 2009, specializes in delivering actionable insights from data.

View Profile

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$12699

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –